Within some months from now I suspect. What we haven't done is patent it. I suppose so, yes. No, they can't once it's published. You can only patent it if it's new.
Patent law is a bit different in Europe.
I have to say that a fair number of my molecular neuroscience colleagues, mainly on this side of the water, have got companies in which they're trying to develop molecules which will do this sort of thing. That's fine, but I would prefer to publish in the scientific press and develop things that way. That's a different story. People are unclear about what we mean by a memory-enhancing drug. If you take someone with Alzheimer's Disease, then the first problems that people notice are things like you don't know where you've left your car keys, whether you've done your shopping this morning, whether you know the person who's ringing your front doorbell.